Acute Ocular Pain Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Formosa Pharmaceuticals, Surface Ophthalmics, SPARC, Visiox

DelveInsight's "Acute Ocular Pain Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Acute Ocular Pain, historical and forecasted epidemiology as well as the Acute Ocular Pain market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Acute Ocular Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Ocular Pain Market Forecast
https://www.delveinsight.com/sample-request/acute-ocular-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Acute Ocular Pain Market Report:
• The Acute Ocular Pain market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2025, OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing novel treatments for neuropathic corneal pain (NCP), a severe ocular condition with no FDA-approved therapy, and inflammatory dry eye disease (DED), a multi-billion-dollar market, has announced a clinical update along with its interim results for the six months ending September 30, 2024.
• In October 2024, OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical company specializing in ophthalmology and developing OK-101 for corneal neuropathic pain (NCP)-an ocular condition that causes pain but lacks an FDA-approved treatment-has announced that the first patient has been dosed in the Phase 2 trial of topical ocular OK-101 for NCP. The Phase 2 study is a double-masked, randomized, 12-week, placebo-controlled trial involving 48 NCP patients, with the condition confirmed through confocal microscopy.
• In May 2024, Formosa Pharmaceuticals has obtained an exclusive licensing agreement with Tabuk Pharmaceuticals for the commercialization rights of clobetasol propionate ophthalmic suspension, 0.05% (APP13007), in significant areas of the Middle East and North Africa (MENA). This advanced medication, which received FDA approval in March 2024, is designed to address inflammation and pain following ocular surgery.
• In 2023, the Acute Ocular Pain market in the US was valued at approximately USD 260 billion.
• Within the EU4 and the UK, Germany leads the Acute Ocular Pain market with a valuation of approximately USD 19 billion, followed by France at around USD 16 billion and Italy at approximately USD 15 billion.
• In 2023, conjunctivitis constituted about 34% of cases of acute ocular pain among prevalent eye disorders.
• In 2023, the United States had the highest prevalence of acute ocular pain cases among the 7MM.
• In 2023, within the EU4 and the UK, Germany reported the highest prevalence of acute ocular pain cases.
• At present, acute ocular pain is managed using NSAIDs, steroids, and other medications like antibiotics. These treatments are categorized into mono-therapies and combination therapies.
• In 2023, conjunctivitis linked to acute operative pain was estimated to affect around 2 million cases, making it the most common condition among similar disorders. This was followed by dry eye disease, with nearly 1 million cases, and corneal aberrations surgery, which accounted for approximately 733,000 cases in the US.
• In the EU4 and the UK, Germany reported the highest number of acute ocular pain cases associated with major eye disorders, estimated at nearly 1 million. France and Italy followed, with approximately 830,000 and 803,000 cases, respectively, highlighting a significant prevalence of acute ocular pain in these countries.
• In 2023, Japan reported approximately 870,000 cases of acute ocular pain associated with major eye disorders. This number is anticipated to rise by 2034 due to the increasing prevalence of an aging population in Japan, which faces a higher risk of experiencing acute ocular pain.
• Recently approved medications such as DEXTENZA, INVELTYS, and LOTEMAX SM are specifically designed to address post-operative pain management following ocular surgery. Additionally, ongoing research is exploring other potential therapies for pain management, including APP13007, SURF-201, and SDN-037.
• Key Acute Ocular Pain Companies: Oculis, Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, and others
• Key Acute Ocular Pain Therapies: OCS-01, APP13007, SURF-201, SDN-037, DEXTENZA (dexamethasone ophthalmic insert), INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121), BROMSITE (bromfenac ophthalmic solution), LOTEMAX SM (loteprednol etabonate ophthalmic gel), PROLENSA (bromfenac ophthalmic solution) 0.07%, and others
• The Acute Ocular Pain epidemiology based on gender analyzed that Acute Ocular Pain affects males and females equally
• The Acute Ocular Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Ocular Pain pipeline products will significantly revolutionize the Acute Ocular Pain market dynamics.

Acute Ocular Pain Overview
Acute ocular pain refers to sudden, sharp, or severe pain in the eye or around the eye area. It can be caused by various conditions affecting the eye, eyelids, or surrounding structures. Common causes of acute ocular pain include corneal abrasions, foreign bodies in the eye, infections such as conjunctivitis or keratitis, trauma or injury to the eye, acute glaucoma, and uveitis.

Get a Free sample for the Acute Ocular Pain Market Report:
https://www.delveinsight.com/report-store/acute-ocular-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Ocular Pain Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Ocular Pain Epidemiology Segmentation:
The Acute Ocular Pain market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Acute Ocular Pain
• Prevalent Cases of Acute Ocular Pain by severity
• Gender-specific Prevalence of Acute Ocular Pain
• Diagnosed Cases of Episodic and Chronic Acute Ocular Pain

Download the report to understand which factors are driving Acute Ocular Pain epidemiology trends @ Acute Ocular Pain Epidemiology Forecast
https://www.delveinsight.com/sample-request/acute-ocular-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Ocular Pain Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Ocular Pain market or expected to get launched during the study period. The analysis covers Acute Ocular Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Ocular Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Ocular Pain Therapies and Key Companies
• OCS-01: Oculis
• APP13007: Formosa Pharmaceuticals
• SURF-201: Surface Ophthalmics
• SDN-037: Sun Pharma Advanced Research Company Ltd (SPARC)
• DEXTENZA (dexamethasone ophthalmic insert): Ocular Therapeutix
• INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121): Kala Pharmaceuticals
• BROMSITE (bromfenac ophthalmic solution): Sun Pharmaceutical
• LOTEMAX SM (loteprednol etabonate ophthalmic gel): Bausch & Lomb
• PROLENSA (bromfenac ophthalmic solution) 0.07%: Bausch & Lomb

Discover more about therapies set to grab major Acute Ocular Pain market share @ Acute Ocular Pain Treatment Market
https://www.delveinsight.com/sample-request/acute-ocular-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Acute Ocular Pain Market Strengths
• Strong guidelines and management has been described for differential diagnosis of acute ocular pain.
• Research and development is increasing the demand for better treatment options for acute ocular pain.

Acute Ocular Pain Market opportunities
• The current market does not have an approved therapy, particularly for the disease. Most of the available treatments target the disease or conditions causing acute ocular pain, thus creating a lucrative market opportunity.
• As the lifestyle of people is changing day by day, people are moving towards unhygienic lifestyle which has increased the chances of bacterial and fungal infections, leading to more and more eye infections.

Scope of the Acute Ocular Pain Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Acute Ocular Pain Companies: Oculis, Formosa Pharmaceuticals, Surface Ophthalmics, Sun Pharma Advanced Research Company Ltd (SPARC), Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, and others
• Key Acute Ocular Pain Therapies: OCS-01, APP13007, SURF-201, SDN-037, DEXTENZA (dexamethasone ophthalmic insert), INVELTYS (loteprednol etabonate ophthalmic suspension/KPI-121), BROMSITE (bromfenac ophthalmic solution), LOTEMAX SM (loteprednol etabonate ophthalmic gel), PROLENSA (bromfenac ophthalmic solution) 0.07%, and others
• Acute Ocular Pain Therapeutic Assessment: Acute Ocular Pain current marketed and Acute Ocular Pain emerging therapies
• Acute Ocular Pain Market Dynamics: Acute Ocular Pain market drivers and Acute Ocular Pain market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Acute Ocular Pain Unmet Needs, KOL's views, Analyst's views, Acute Ocular Pain Market Access and Reimbursement

To know more about Acute Ocular Pain companies working in the treatment market, visit @ Acute Ocular Pain Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/acute-ocular-pain-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Acute Ocular Pain Market Report Introduction
2. Executive Summary for Acute Ocular Pain
3. SWOT analysis of Acute Ocular Pain
4. Acute Ocular Pain Patient Share (%) Overview at a Glance
5. Acute Ocular Pain Market Overview at a Glance
6. Acute Ocular Pain Disease Background and Overview
7. Acute Ocular Pain Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Ocular Pain
9. Acute Ocular Pain Current Treatment and Medical Practices
10. Acute Ocular Pain Unmet Needs
11. Acute Ocular Pain Emerging Therapies
12. Acute Ocular Pain Market Outlook
13. Country-Wise Acute Ocular Pain Market Analysis (2020-2034)
14. Acute Ocular Pain Market Access and Reimbursement of Therapies
15. Acute Ocular Pain Market Drivers
16. Acute Ocular Pain Market Barriers
17. Acute Ocular Pain Appendix
18. Acute Ocular Pain Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight
• Female Infertility Market: https://www.delveinsight.com/report-store/female-infertility-market
• Gonorrhea Market: https://www.delveinsight.com/report-store/gonorrhea-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Structural Heart Devices Market: https://www.delveinsight.com/report-store/structural-heart-devices-market-market
• Prosthetic Heart Valve Market: https://www.delveinsight.com/report-store/prosthetic-heart-valve-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Cardiac Arrythmia Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.